title: A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia.
abstract: Objectives. Dutasteride, a dual 5α-reductase inhibitor, is used to treat benign prostatic hyperplasia. Nevertheless, its histopathological effects on the morphometrics of blood vessels and glands are still controversial. The aim here was to assess the histopathological effects of dutasteride in cases of benign prostatic hyperplasia in a retrospective study. Methods. Patients with benign prostatic hyperplasia more than 40 cm(3) in prostatic volume were administered 0.5 mg of dutasteride daily or left untreated prior to receiving a transurethral resection of the prostate. Images of sections stained with hematoxylin/eosin and with anti-CD31 antibody were analyzed. Results. In the dutasteride-treated group, the duration of administration was 16.3 ± 8.1 weeks. Artery/arteriole density and vein/venule density in benign prostatic tissue were both lower in the dutasteride-treated group than in the control group. The vein/venule area as a percentage of the whole area was also lower in the dutasteride-treated group, while the artery/arteriole area did not show a significant difference. Glandular/CD31-expressing vessel densities as well as glandular/CD31-expressing vessel areas were comparable between the two groups. Conclusions. Dutasteride reduced the artery/arteriole and vein/venule densities and the proportion of vein/venule area in the tissue of patients with benign prostatic hyperplasia.
authors: Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan.
authors: Masayoshi
authors: M
authors: Zaitsu
authors: Akiko
authors: A
authors: Tonooka
authors: Koji
authors: K
authors: Mikami
authors: Mami
authors: M
authors: Hattori
authors: Yuta
authors: Y
authors: Takeshima
authors: Toshimasa
authors: T
authors: Uekusa
authors: Takumi
authors: T
authors: Takeuchi
references: Nat Clin Pract Urol. 2006 Sep;3(9):495-503
references: 16964191
references: FASEB J. 2002 Aug;16(10):1271-3
references: 12060670
references: BJU Int. 2007 Mar;99(3):587-94
references: 17407516
references: Endocrinology. 2008 Jun;149(6):2959-69
references: 18292195
references: BJU Int. 2005 Dec;96(9):1319-22
references: 16287453
references: Scand J Urol Nephrol. 2009;43(6):445-53
references: 19968580
references: Biomed Sci Instrum. 2012;48:49-56
references: 22846264
references: Drugs. 2008;68(4):463-85
references: 18318566
references: Curr Top Med Chem. 2006;6(5):405-21
references: 16719800
references: J Urol. 2004 Sep;172(3):915-9
references: 15310997
references: J Pharmacol Exp Ther. 1997 Sep;282(3):1496-502
references: 9316864
references: N Engl J Med. 2012 Jul 19;367(3):248-57
references: 22808960
references: J Urol. 2004 Oct;172(4 Pt 1):1399-403
references: 15371854
references: Am J Pathol. 2006 Mar;168(3):1045-53
references: 16507917
references: J Biol Chem. 1993 Aug 15;268(23):17404-12
references: 8394341
references: Endocr Relat Cancer. 2010 Aug 16;17(3):757-70
references: 20519274
references: Radiat Oncol. 2012 May 23;7:75
references: 22621752
references: Prostate. 1998 Aug 1;36(3):201-6
references: 9687993
references: Urology. 2009 Jun;73(6):1274-8
references: 19375786
references: N Engl J Med. 2010 Apr 1;362(13):1192-202
references: 20357281
references: Annu Rev Biochem. 1994;63:25-61
references: 7979239
references: Urology. 2006 Aug;68(2):436-41
references: 16904480
references: J Clin Endocrinol Metab. 2004 May;89(5):2179-84
references: 15126539
references: Prostate Suppl. 1996;6:88-92
references: 8630237